U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C13H13N3O3
Molecular Weight 259.2611
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LENALIDOMIDE

SMILES

c1cc2c(CN(C3CCC(=NC3=O)O)C2=O)c(c1)N

InChI

InChIKey=GOTYRUGSSMKFNF-UHFFFAOYSA-N
InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)

HIDE SMILES / InChI

Molecular Formula C13H13N3O3
Molecular Weight 259.2611
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment:: http://www.revlimidrems.com/

Lenalidomide (trade name Revlimid) is a derivative of thalidomide introduced in 2004. It is an immunomodulatory agent with anti-angiogenic properties. Revlimid in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM) who have received at least one prior therapy. Also is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. In addition, Revlimid is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. The mechanism of action of lenalidomide remains to be fully characterized. Lenalidomide inhibited the secretion of pro-inflammatory cytokines and increased the secretion of anti-inflammatory cytokines from peripheral blood mononuclear cells. Lenalidomide causes a delay in tumor growth in some in vivo nonclinical hematopoietic tumor models including multiple myeloma. Immunomodulatory properties of lenalidomide include activation of T cells and natural killer (NK) cells, increased numbers of NKT cells, and inhibition of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes. In multiple myeloma cells, the combination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis. Recently was discovered, that protein cereblon (CRBN) is a proximate, therapeutically important molecular target of lenalidomide. Low CRBN expression was found to correlate with drug resistance in multiple myeloma (MM) cell lines and primary MM cells. One of the downstream targets of CRBN identified is interferon regulatory factor 4 (IRF4), which is critical for myeloma cell survival and is down-regulated by (immune-modulatory drugs) treatment. CRBN is also implicated in several effects of immunomodulatory drugs, such as down-regulation of tumor necrosis factor-α (TNF-α) and T cell immunomodulatory activity, demonstrating that the pleotropic actions of the immunomodulatory drugs (IMiDs) are initiated by binding to CRBN. Future dissection of CRBN downstream signaling will help to delineate the underlying mechanisms for IMiD action and eventually lead to development of new drugs with more specific anti-myeloma activities. It may also provide a biomarker to predict IMiD response and resistance. Lenalidomide also inhibited the expression of cyclooxygenase-2 (COX-2) but not COX-1 in vitro.

CNS Activity

Curator's Comment:: CSF-to-plasma ratio for lenalidomide of 0·10. In comparison to drugs whose CNS activity is known, lenalidomide has moderate CNS penetrability.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q96SW2
Gene ID: 51185
Gene Symbol: CRBN
Target Organism: Homo sapiens (Human)
3 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
REVLIMID

Approved Use

REVLIMID is a thalidomide analogue indicated for the treatment of patients with: Multiple myeloma (MM), in combination with dexamethasone (1.1). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities (1.2). Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib (1.3). Limitations of Use: REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials (1.4). 1.1 Multiple Myeloma REVLIMID in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM). 1.2 Myelodysplastic Syndromes REVLIMID is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. 1.3 Mantle Cell Lymphoma REVLIMID is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. 1.4 Limitations of Use: REVLIMID is not indicated and is not recommended for the treatment of patients with CLL outside of controlled clinical trials [see Warnings and Precautions (5.5)

Launch Date

1135641600000
Primary
REVLIMID

Approved Use

REVLIMID is a thalidomide analogue indicated for the treatment of patients with: Multiple myeloma (MM), in combination with dexamethasone (1.1). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities (1.2). Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib (1.3). Limitations of Use: REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials (1.4). 1.1 Multiple Myeloma REVLIMID in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM). 1.2 Myelodysplastic Syndromes REVLIMID is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. 1.3 Mantle Cell Lymphoma REVLIMID is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. 1.4 Limitations of Use: REVLIMID is not indicated and is not recommended for the treatment of patients with CLL outside of controlled clinical trials [see Warnings and Precautions (5.5)

Launch Date

1135641600000
Primary
REVLIMID

Approved Use

REVLIMID is a thalidomide analogue indicated for the treatment of patients with: Multiple myeloma (MM), in combination with dexamethasone (1.1). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities (1.2). Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib (1.3). Limitations of Use: REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials (1.4). 1.1 Multiple Myeloma REVLIMID in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM). 1.2 Myelodysplastic Syndromes REVLIMID is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. 1.3 Mantle Cell Lymphoma REVLIMID is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. 1.4 Limitations of Use: REVLIMID is not indicated and is not recommended for the treatment of patients with CLL outside of controlled clinical trials [see Warnings and Precautions (5.5)

Launch Date

1135641600000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
433.1 ng/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LENALIDOMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1252.08 ng/mL
2 mg/kg single, oral
dose: 2 mg/kg
route of administration: oral
experiment type: single
co-administered:
LENALIDOMIDE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1472.4 ng × h/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LENALIDOMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5378.83 ng*h/mL
2 mg/kg single, oral
dose: 2 mg/kg
route of administration: oral
experiment type: single
co-administered:
LENALIDOMIDE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LENALIDOMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
70%
LENALIDOMIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
25 mg 1 times / day multiple, oral
Highest studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
unhealthy, 35 years (range: 20-70years)
Health Status: unhealthy
Age Group: 35 years (range: 20-70years)
Sex: M+F
Sources:
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
pregnant, adult
Health Status: pregnant
Age Group: adult
Sex: F
Sources:
Other AEs: Birth defects...
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Disc. AE: Thrombocytopenia, Neutropenia...
AEs leading to
discontinuation/dose reduction:
Thrombocytopenia (6.1%)
Neutropenia (3.5%)
Rash (2%)
Nausea (1.5%)
Diarrhea (1.3%)
Fatigue (1%)
Anaemia NOS (1%)
Abdominal distension (1%)
Pyrexia (0.8%)
Dyspnea (0.8%)
Cough (0.5%)
Abdominal pain NOS (0.5%)
Face edema (0.5%)
Pruritus (0.5%)
Anemia hemolytic (NOS) (0.5%)
Pneumonia NOS (1%)
Arthralgia (0.5%)
Sources:
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Other AEs: Neutropenia, Thrombocytopenia...
Other AEs:
Neutropenia
Thrombocytopenia
Thrombosis venous deep
Pulmonary embolism
Sources:
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Joint sprain, Foot fracture...
Other AEs:
Joint sprain (serious, 2 patients)
Foot fracture (serious, 1 patient)
Thrombosis (serious, 1 patient)
Blood human chorionic gonadotropin positive (serious, 1 patient)
Blood potassium decreased (serious, 1 patient)
Pregnancy test false positive (serious, 1 patient)
Sick sinus syndrome (serious, 1 patient)
Pregnancy NOS (serious, 2 patients)
Abortion spontaneous NOS (serious, 1 patient)
Pain NOS (serious, 1 patient)
Arthritis NOS (serious, 1 patient)
Angioneurotic edema (serious, 1 patient)
Rash NOS (below serious, 24 patients)
Pruritus (below serious, 8 patients)
Dry skin (below serious, 6 patients)
Diarrhoea NOS (below serious, 11 patient)
Constipation (below serious, 8 patients)
Vomiting NOS (below serious, 5 patients)
Dizziness (below serious, 9 patients)
Pyrexia (below serious, 6 patients)
Nasopharyngitis (below serious, 6 patients)
Pharyngitis (below serious, 6 patients)
Sinusitis NOS (below serious, 5 patients)
Alanine aminotransferase increased (below serious, 5 patients)
Cramp muscle (below serious, 5 patients)
Insomnia (below serious, 7 patients)
Sources:
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Fatigue, General physical health deterioration...
Other AEs:
Fatigue (serious, 1 patient)
General physical health deterioration (serious, 2 patients)
Mucosal inflammation (serious, 1 patient)
Pneumonia (serious, 3 patients)
Anal abscess (serious, 1 patient)
Bacteraemia (serious, 1 patient)
Cellulitis (serious, 1 patient)
Erysipelas (serious, 1 patient)
Gastroenteritis (serious, 1 patient)
Pneumonia legionella (serious, 1 patient)
Pyelonephritis (serious, 1 patient)
Septic shock (serious, 2 patients)
Urinary tract infection (serious, 1 patient)
Epistaxis (serious, 1 patient)
Lung disorder (serious, 1 patient)
Pulmonary embolism (serious, 2 patients)
Acute myeloid leukaemia (serious, 8 patients)
Bladder cancer (serious, 1 patient)
Breast cancer (serious, 1 patient)
Colon cancer (serious, 1 patient)
Colorectal cancer (serious, 1 patient)
Histiocytosis haematophagic (serious, 1 patient)
Refractory anaemia with an excess of blasts (serious, 2 patients)
Confusional state (serious, 1 patient)
Delirium (serious, 1 patient)
Altered mood (serious, 1 patient)
Acute myocardial infarction (serious, 2 patients)
Cardiac failure (serious, 1 patient)
Myocardial infarction (serious, 1 patient)
Tachyarrhythmia (serious, 1 patient)
Abdominal pain (serious, 1 patient)
Abdominal pain upper (serious, 1 patient)
Colitis (serious, 1 patient)
Constipation (serious, 1 patient)
Diarrhoea (serious, 3 patients)
Intestinal obstruction (serious, 1 patient)
Femoral neck fracture (serious, 1 patient)
Humerus fracture (serious, 1 patient)
Spinal compression fracture (serious, 1 patient)
Subdural haematoma (serious, 1 patient)
Synovial rupture (serious, 1 patient)
Hyperglycaemia (serious, 1 patient)
Cerebral haemorrhage (serious, 1 patient)
Cerebrovascular accident (serious, 1 patient)
Coma (serious, 1 patient)
Headache (serious, 1 patient)
Colic renal (serious, 1 patient)
Renal failure (serious, 1 patient)
Stress urinary incontinence (serious, 1 patient)
Deep vein thrombosis (serious, 4 patients)
Arterial occlusive disease (serious, 1 patient)
Hypotension (serious, 1 patient)
Orthostatic hypotension (serious, 1 patient)
Anaemia (serious, 1 patient)
Autoimmune thrombocytopenia (serious, 1 patient)
Bone marrow failure (serious, 1 patient)
Febrile neutropenia (serious, 2 patients)
Haemolysis (serious, 1 patient)
Neutropenia (serious, 5 patients)
Pancytopenia (serious, 1 patient)
Splenomegaly (serious, 1 patient)
Thrombocytopenia (serious, 3 patients)
Arthritis (serious, 1 patient)
Back pain (serious, 2 patients)
Joint range of motion decreased (serious, 1 patient)
Musculoskeletal pain (serious, 1 patient)
Skin ulcer (serious, 1 patient)
Urticaria (serious, 1 patient)
Diarrhoea (below serious, 37 patients)
Nausea (below serious, 21 patient)
Constipation (below serious, 19 patients)
Abdominal pain (below serious, 14 patients)
Vomiting (below serious, 9 patients)
Dry mouth (below serious, 5 patients)
Abdominal pain upper (below serious, 8 patients)
Dyspepsia (below serious, 5 patients)
Flatulence (below serious, 1 patient)
Fatigue (below serious, 17 patients)
Oedema peripheral (below serious, 13 patients)
Pyrexia (below serious, 16 patients)
Influenza like illness (below serious, 5 patients)
Oedema (below serious, 4 patients)
Pain (below serious, 4 patients)
Neutropenia (below serious, 57 patients)
Leukopenia (below serious, 8 patients)
Thrombocytopenia (below serious, 36 patients)
Nasopharyngitis (below serious, 16 patients)
Upper respiratory tract infection (below serious, 12 patients)
Urinary tract infection (below serious, 12 patients)
Bronchitis (below serious, 14 patients)
Cystitis (below serious, 4 patients)
Lower respiratory tract infection (below serious, 5 patients)
Respiratory tract infection (below serious, 3 patients)
Sinusitis (below serious, 6 patients)
Gastroenteritis (below serious, 6 patients)
Influenza (below serious, 5 patients)
Pharyngitis (below serious, 4 patients)
Rhinitis (below serious, 3 patients)
Headache (below serious, 14 patients)
Dizziness (below serious, 10 patients)
Sciatica (below serious, 4 patients)
Balance disorder (below serious, 4 patients)
Peripheral sensory neuropathy (below serious, 1 patient)
Muscle spasms (below serious, 15 patients)
Back pain (below serious, 8 patients)
Myalgia (below serious, 6 patients)
Arthralgia (below serious, 5 patients)
Pain in extremity (below serious, 10 patients)
Musculoskeletal chest pain (below serious, 5 patients)
Neck pain (below serious, 3 patients)
Decreased appetite (below serious, 8 patients)
Iron overload (below serious, 5 patients)
Hypoalbuminaemia (below serious, 1 patient)
Hypokalaemia (below serious, 3 patients)
Hypomagnesaemia (below serious, 3 patients)
Cough (below serious, 10 patients)
Dyspnoea (below serious, 9 patients)
Epistaxis (below serious, 4 patients)
Dyspnoea exertional (below serious, 3 patients)
Oropharyngeal pain (below serious, 6 patients)
Pruritus (below serious, 20 patients)
Dry skin (below serious, 10 patients)
Rash (below serious, 12 patients)
Alopecia (below serious, 4 patients)
Hyperhidrosis (below serious, 4 patients)
Petechiae (below serious, 4 patients)
Insomnia (below serious, 9 patients)
Anxiety (below serious, 5 patients)
Contusion (below serious, 4 patients)
Fall (below serious, 4 patients)
Joint sprain (below serious, 1 patient)
Wound (below serious, 4 patients)
Alanine aminotransferase increased (below serious, 5 patients)
Weight decreased (below serious, 5 patients)
Haematoma (below serious, 6 patients)
Phlebitis (below serious, 4 patients)
Hypertension (below serious, 9 patients)
Cataract (below serious, 5 patients)
Conjunctivitis (below serious, 5 patients)
Dysuria (below serious, 3 patients)
Vertigo (below serious, 3 patients)
Musculoskeletal pain (below serious, 11 patient)
Sources:
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Squamous cell carcinoma, Herpes zoster...
Other AEs:
Squamous cell carcinoma (serious, 1 patient)
Herpes zoster (below serious, 1 patient)
Herpes zoster ophthalmic (below serious, 1 patient)
Viral rash (below serious, 1 patient)
Thrombocytopenia (below serious, 1 patient)
Neutropenia (below serious, 1 patient)
Constipation (below serious, 1 patient)
Abdominal pain upper (below serious, 1 patient)
Diarrhoea (below serious, 1 patient)
Dry mouth (below serious, 1 patient)
Flatulence (below serious, 1 patient)
Stomatitis (below serious, 1 patient)
Chills (below serious, 1 patient)
Oedema peripheral (below serious, 1 patient)
Dysgeusia (below serious, 1 patient)
Peripheral sensory neuropathy (below serious, 1 patient)
Eczema (below serious, 1 patient)
Rash (below serious, 1 patient)
Conjunctivitis (below serious, 1 patient)
Muscle spasms (below serious, 1 patient)
Neck pain (below serious, 1 patient)
Basal cell carcinoma (below serious, 1 patient)
Malignant melanoma (below serious, 1 patient)
Libido decreased (below serious, 1 patient)
Erectile dysfunction (below serious, 1 patient)
Sources:
25 mg 1 times / day steady, oral
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Bleeding, Ischemic colitis...
Other AEs:
Bleeding (serious, 1 patient)
Ischemic colitis (serious, 1 patient)
Sources:
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Pyrexia, Generalised oedema...
Other AEs:
Pyrexia (serious, 5 patients)
Generalised oedema (serious, 1 patient)
Non-cardiac chest pain (serious, 1 patient)
Pneumonia (serious, 5 patients)
Erysipelas (serious, 1 patient)
Gastroenteritis (serious, 1 patient)
Infection (serious, 1 patient)
Lower respiratory tract infection (serious, 1 patient)
Respiratory tract infection (serious, 1 patient)
Staphylococcal sepsis (serious, 1 patient)
Urinary tract infection (serious, 3 patients)
Urosepsis (serious, 1 patient)
Chronic obstructive pulmonary disease (serious, 1 patient)
Hypoxia (serious, 1 patient)
Lung disorder (serious, 1 patient)
Aspiration pneumonia (serious, 1 patient)
Pulmonary embolism (serious, 3 patients)
Respiratory failure (serious, 1 patient)
Acute myeloid leukaemia (serious, 8 patients)
Leukaemia (serious, 1 patient)
Lung cancer metastatic (serious, 1 patient)
Myelodysplastic syndrome (serious, 1 patient)
Refractory anaemia with an excess of blasts (serious, 1 patient)
Anxiety disorder (serious, 1 patient)
Altered mood (serious, 1 patient)
Atrial fibrillation (serious, 2 patients)
Cardiac failure (serious, 2 patients)
Diarrhoea (serious, 1 patient)
Intussusception (serious, 1 patient)
Tooth disorder (serious, 1 patient)
Fall (serious, 1 patient)
Injury (serious, 1 patient)
Transfusion reaction (serious, 1 patient)
Diabetes mellitus inadequate control (serious, 1 patient)
Hyperglycaemia (serious, 1 patient)
Hypoglycaemia (serious, 1 patient)
Headache (serious, 1 patient)
Renal failure (serious, 1 patient)
Urinary incontinence (serious, 1 patient)
Phlebitis (serious, 1 patient)
Venous thrombosis (serious, 1 patient)
Anaemia (serious, 4 patients)
Febrile neutropenia (serious, 2 patients)
Neutropenia (serious, 5 patients)
Pancytopenia (serious, 1 patient)
Thrombocytopenia (serious, 6 patients)
International normalised ratio increased (serious, 1 patient)
Urine human chorionic gonadotropin abnormal (serious, 1 patient)
Fibromyalgia (serious, 1 patient)
Muscle spasms (serious, 1 patient)
Myalgia (serious, 1 patient)
Pyoderma gangrenosum (serious, 1 patient)
Cytogenetic abnormality (serious, 1 patient)
Diarrhoea (below serious, 32 patients)
Nausea (below serious, 16 patients)
Constipation (below serious, 18 patients)
Abdominal pain (below serious, 7 patients)
Vomiting (below serious, 8 patients)
Dry mouth (below serious, 4 patients)
Abdominal pain upper (below serious, 8 patients)
Dyspepsia (below serious, 4 patients)
Flatulence (below serious, 2 patients)
Fatigue (below serious, 17 patients)
Oedema peripheral (below serious, 15 patients)
Pyrexia (below serious, 11 patient)
Non-cardiac chest pain (below serious, 5 patients)
Influenza like illness (below serious, 5 patients)
Oedema (below serious, 3 patients)
Pain (below serious, 1 patient)
Neutropenia (below serious, 55 patients)
Anaemia (below serious, 10 patients)
Leukopenia (below serious, 12 patients)
Thrombocytopenia (below serious, 38 patients)
Nasopharyngitis (below serious, 15 patients)
Upper respiratory tract infection (below serious, 11 patient)
Urinary tract infection (below serious, 6 patients)
Bronchitis (below serious, 7 patients)
Cystitis (below serious, 2 patients)
Lower respiratory tract infection (below serious, 2 patients)
Respiratory tract infection (below serious, 9 patients)
Gastroenteritis (below serious, 7 patients)
Gastroenteritis viral (below serious, 4 patients)
Influenza (below serious, 5 patients)
Oral herpes (below serious, 6 patients)
Pharyngitis (below serious, 3 patients)
Rhinitis (below serious, 4 patients)
Headache (below serious, 12 patients)
Dizziness (below serious, 8 patients)
Paraesthesia (below serious, 8 patients)
Peripheral sensory neuropathy (below serious, 4 patients)
Muscle spasms (below serious, 12 patients)
Back pain (below serious, 12 patients)
Myalgia (below serious, 4 patients)
Arthralgia (below serious, 6 patients)
Pain in extremity (below serious, 5 patients)
Musculoskeletal chest pain (below serious, 1 patient)
Neck pain (below serious, 3 patients)
Decreased appetite (below serious, 8 patients)
Iron overload (below serious, 4 patients)
Hypoalbuminaemia (below serious, 4 patients)
Hypokalaemia (below serious, 7 patients)
Hypomagnesaemia (below serious, 3 patients)
Cough (below serious, 12 patients)
Dyspnoea (below serious, 12 patients)
Epistaxis (below serious, 3 patients)
Dyspnoea exertional (below serious, 4 patients)
Oropharyngeal pain (below serious, 7 patients)
Pruritus (below serious, 16 patients)
Dry skin (below serious, 10 patients)
Rash (below serious, 18 patients)
Hyperhidrosis (below serious, 2 patients)
Petechiae (below serious, 3 patients)
Insomnia (below serious, 6 patients)
Depression (below serious, 4 patients)
Anxiety (below serious, 3 patients)
Contusion (below serious, 3 patients)
Fall (below serious, 2 patients)
Wound (below serious, 2 patients)
Alanine aminotransferase increased (below serious, 7 patients)
Weight decreased (below serious, 6 patients)
Haematoma (below serious, 6 patients)
Hypertension (below serious, 7 patients)
Cataract (below serious, 1 patient)
Vertigo (below serious, 8 patients)
Musculoskeletal pain (below serious, 5 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Birth defects serious
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
pregnant, adult
Health Status: pregnant
Age Group: adult
Sex: F
Sources:
Abdominal pain NOS 0.5%
Disc. AE
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Anemia hemolytic (NOS) 0.5%
Disc. AE
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Arthralgia 0.5%
Disc. AE
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Cough 0.5%
Disc. AE
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Face edema 0.5%
Disc. AE
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Pruritus 0.5%
Disc. AE
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Dyspnea 0.8%
Disc. AE
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Pyrexia 0.8%
Disc. AE
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Abdominal distension 1%
Disc. AE
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Anaemia NOS 1%
Disc. AE
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Fatigue 1%
Disc. AE
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Pneumonia NOS 1%
Disc. AE
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Diarrhea 1.3%
Disc. AE
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Nausea 1.5%
Disc. AE
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Rash 2%
Disc. AE
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Neutropenia 3.5%
Disc. AE
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Thrombocytopenia 6.1%
Disc. AE
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
Neutropenia
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Pulmonary embolism
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Thrombocytopenia
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Thrombosis venous deep
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
Diarrhoea NOS below serious, 11 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Rash NOS below serious, 24 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Alanine aminotransferase increased below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cramp muscle below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Sinusitis NOS below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Vomiting NOS below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dry skin below serious, 6 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Nasopharyngitis below serious, 6 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pharyngitis below serious, 6 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pyrexia below serious, 6 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Insomnia below serious, 7 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Constipation below serious, 8 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pruritus below serious, 8 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dizziness below serious, 9 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Abortion spontaneous NOS serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Angioneurotic edema serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Arthritis NOS serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Blood human chorionic gonadotropin positive serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Blood potassium decreased serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Foot fracture serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pain NOS serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pregnancy test false positive serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Sick sinus syndrome serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Thrombosis serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Joint sprain serious, 2 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pregnancy NOS serious, 2 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Flatulence below serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hypoalbuminaemia below serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Joint sprain below serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Peripheral sensory neuropathy below serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cough below serious, 10 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dizziness below serious, 10 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dry skin below serious, 10 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pain in extremity below serious, 10 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Musculoskeletal pain below serious, 11 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Rash below serious, 12 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Upper respiratory tract infection below serious, 12 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Urinary tract infection below serious, 12 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Oedema peripheral below serious, 13 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Abdominal pain below serious, 14 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Bronchitis below serious, 14 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Headache below serious, 14 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Muscle spasms below serious, 15 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Nasopharyngitis below serious, 16 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pyrexia below serious, 16 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Fatigue below serious, 17 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Constipation below serious, 19 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pruritus below serious, 20 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Nausea below serious, 21 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dyspnoea exertional below serious, 3 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dysuria below serious, 3 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hypokalaemia below serious, 3 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hypomagnesaemia below serious, 3 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Neck pain below serious, 3 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Respiratory tract infection below serious, 3 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Rhinitis below serious, 3 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Vertigo below serious, 3 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Thrombocytopenia below serious, 36 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Diarrhoea below serious, 37 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Alopecia below serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Balance disorder below serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Contusion below serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cystitis below serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Epistaxis below serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Fall below serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hyperhidrosis below serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Oedema below serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pain below serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Petechiae below serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pharyngitis below serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Phlebitis below serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Sciatica below serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Wound below serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Alanine aminotransferase increased below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Anxiety below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Arthralgia below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cataract below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Conjunctivitis below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dry mouth below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dyspepsia below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Influenza like illness below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Influenza below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Iron overload below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Lower respiratory tract infection below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Musculoskeletal chest pain below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Weight decreased below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Neutropenia below serious, 57 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Gastroenteritis below serious, 6 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Haematoma below serious, 6 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Myalgia below serious, 6 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Oropharyngeal pain below serious, 6 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Sinusitis below serious, 6 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Abdominal pain upper below serious, 8 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Back pain below serious, 8 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Decreased appetite below serious, 8 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Leukopenia below serious, 8 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dyspnoea below serious, 9 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hypertension below serious, 9 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Insomnia below serious, 9 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Vomiting below serious, 9 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Abdominal pain upper serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Abdominal pain serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Altered mood serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Anaemia serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Anal abscess serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Arterial occlusive disease serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Arthritis serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Autoimmune thrombocytopenia serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Bacteraemia serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Bladder cancer serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Bone marrow failure serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Breast cancer serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cardiac failure serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cellulitis serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cerebral haemorrhage serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cerebrovascular accident serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Colic renal serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Colitis serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Colon cancer serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Colorectal cancer serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Coma serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Confusional state serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Constipation serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Delirium serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Epistaxis serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Erysipelas serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Fatigue serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Femoral neck fracture serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Gastroenteritis serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Haemolysis serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Headache serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Histiocytosis haematophagic serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Humerus fracture serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hyperglycaemia serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hypotension serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Intestinal obstruction serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Joint range of motion decreased serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Lung disorder serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Mucosal inflammation serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Musculoskeletal pain serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Myocardial infarction serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Orthostatic hypotension serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pancytopenia serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pneumonia legionella serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pyelonephritis serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Renal failure serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Skin ulcer serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Spinal compression fracture serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Splenomegaly serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Stress urinary incontinence serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Subdural haematoma serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Synovial rupture serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Tachyarrhythmia serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Urinary tract infection serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Urticaria serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Acute myocardial infarction serious, 2 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Back pain serious, 2 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Febrile neutropenia serious, 2 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
General physical health deterioration serious, 2 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pulmonary embolism serious, 2 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Refractory anaemia with an excess of blasts serious, 2 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Septic shock serious, 2 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Diarrhoea serious, 3 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pneumonia serious, 3 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Thrombocytopenia serious, 3 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Deep vein thrombosis serious, 4 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Neutropenia serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Acute myeloid leukaemia serious, 8 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Abdominal pain upper below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Basal cell carcinoma below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Chills below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Conjunctivitis below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Constipation below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Diarrhoea below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dry mouth below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dysgeusia below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Eczema below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Erectile dysfunction below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Flatulence below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Herpes zoster ophthalmic below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Herpes zoster below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Libido decreased below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Malignant melanoma below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Muscle spasms below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Neck pain below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Neutropenia below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Oedema peripheral below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Peripheral sensory neuropathy below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Rash below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Stomatitis below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Thrombocytopenia below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Viral rash below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Squamous cell carcinoma serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Bleeding serious, 1 patient
25 mg 1 times / day steady, oral
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Ischemic colitis serious, 1 patient
25 mg 1 times / day steady, oral
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cataract below serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Musculoskeletal chest pain below serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pain below serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Anaemia below serious, 10 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dry skin below serious, 10 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pyrexia below serious, 11 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Upper respiratory tract infection below serious, 11 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Back pain below serious, 12 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cough below serious, 12 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dyspnoea below serious, 12 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Headache below serious, 12 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Leukopenia below serious, 12 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Muscle spasms below serious, 12 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Nasopharyngitis below serious, 15 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Oedema peripheral below serious, 15 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Nausea below serious, 16 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pruritus below serious, 16 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Fatigue below serious, 17 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Constipation below serious, 18 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Rash below serious, 18 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cystitis below serious, 2 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Fall below serious, 2 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Flatulence below serious, 2 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hyperhidrosis below serious, 2 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Lower respiratory tract infection below serious, 2 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Wound below serious, 2 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Anxiety below serious, 3 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Contusion below serious, 3 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Epistaxis below serious, 3 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hypomagnesaemia below serious, 3 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Neck pain below serious, 3 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Oedema below serious, 3 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Petechiae below serious, 3 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pharyngitis below serious, 3 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Diarrhoea below serious, 32 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Thrombocytopenia below serious, 38 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Depression below serious, 4 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dry mouth below serious, 4 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dyspepsia below serious, 4 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dyspnoea exertional below serious, 4 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Gastroenteritis viral below serious, 4 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hypoalbuminaemia below serious, 4 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Iron overload below serious, 4 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Myalgia below serious, 4 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Peripheral sensory neuropathy below serious, 4 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Rhinitis below serious, 4 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Influenza like illness below serious, 5 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Influenza below serious, 5 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Musculoskeletal pain below serious, 5 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Non-cardiac chest pain below serious, 5 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pain in extremity below serious, 5 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Neutropenia below serious, 55 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Arthralgia below serious, 6 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Haematoma below serious, 6 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Insomnia below serious, 6 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Oral herpes below serious, 6 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Urinary tract infection below serious, 6 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Weight decreased below serious, 6 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Abdominal pain below serious, 7 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Alanine aminotransferase increased below serious, 7 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Bronchitis below serious, 7 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Gastroenteritis below serious, 7 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hypertension below serious, 7 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hypokalaemia below serious, 7 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Oropharyngeal pain below serious, 7 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Abdominal pain upper below serious, 8 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Decreased appetite below serious, 8 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dizziness below serious, 8 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Paraesthesia below serious, 8 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Vertigo below serious, 8 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Vomiting below serious, 8 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Respiratory tract infection below serious, 9 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Altered mood serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Anxiety disorder serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Aspiration pneumonia serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Chronic obstructive pulmonary disease serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cytogenetic abnormality serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Diabetes mellitus inadequate control serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Diarrhoea serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Erysipelas serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Fall serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Fibromyalgia serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Gastroenteritis serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Generalised oedema serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Headache serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hyperglycaemia serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hypoglycaemia serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Hypoxia serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Infection serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Injury serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
International normalised ratio increased serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Intussusception serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Leukaemia serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Lower respiratory tract infection serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Lung cancer metastatic serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Lung disorder serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Muscle spasms serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Myalgia serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Myelodysplastic syndrome serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Non-cardiac chest pain serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pancytopenia serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Phlebitis serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pyoderma gangrenosum serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Refractory anaemia with an excess of blasts serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Renal failure serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Respiratory failure serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Respiratory tract infection serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Staphylococcal sepsis serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Tooth disorder serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Transfusion reaction serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Urinary incontinence serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Urine human chorionic gonadotropin abnormal serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Urosepsis serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Venous thrombosis serious, 1 patient
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Atrial fibrillation serious, 2 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Cardiac failure serious, 2 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Febrile neutropenia serious, 2 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pulmonary embolism serious, 3 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Urinary tract infection serious, 3 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Anaemia serious, 4 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Neutropenia serious, 5 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pneumonia serious, 5 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Pyrexia serious, 5 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Thrombocytopenia serious, 6 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Acute myeloid leukaemia serious, 8 patients
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
inconclusive
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no (co-administration study)
Comment: enzyme marker ethoxyresorufin O-dealkylase was used
Page: 27
no
no (co-administration study)
Comment: enzyme marker S-mephenytoin 4-hydroxylase
Page: 27
no
no (co-administration study)
Comment: enzyme marker tolbutamide methyl-hydroxylase
Page: 27
no
no (co-administration study)
Comment: enzyme marker bufuralol 1-hydroxylase
Page: 27
no
no (co-administration study)
Comment: enzyme marker lauric acid 11-hjydroxylase
Page: 27
no
no (co-administration study)
Comment: enzyme marker testosterone 6b-hydroxylase
Page: 27
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
inconclusive
no
no
no
no
no
no
no
no
no
no
no
no
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
2002 Nov 1
Circulating endothelial progenitor cells in multiple myeloma: implications and significance.
2005 Apr 15
New treatments for multiple myeloma.
2005 Dec
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
2005 Dec 15
Efficacy of lenalidomide in myelodysplastic syndromes.
2005 Feb 10
Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
2005 Oct
Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-AT.
2005 Oct
Lenalidomide-induced warm autoimmune hemolytic anemia.
2006 Dec 10
Current therapeutic uses of lenalidomide in multiple myeloma.
2006 Feb
Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis.
2006 Jul 1
Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications.
2006 Jul 15
Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis.
2006 Mar 1
Lenalidomide and venous thrombosis in multiple myeloma.
2006 May 11
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
2006 Nov 15
Immunomodulatory drugs (IMiDs): a new treatment option for myelodysplastic syndromes.
2006 Oct
Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma.
2007 Aug
Risk of thrombosis with lenalidomide and its prevention with aspirin.
2007 Jan
Novel therapies in myeloma.
2007 Nov
Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.
2008 Feb
Azotemia associated with use of lenalidomide in plasma cell dyscrasias.
2008 Jun
Thrombosis of the corpora cavernosa complicating lenalidomide therapy of myelofibrosis.
2008 May
Venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniques.
2009
Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
2009 Jan 1
Lenalidomide-induced acute liver failure.
2009 Oct
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
2009 Oct 1
Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD).
2010 Apr
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
2010 Aug 5
Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis.
2010 Jun
Altered expression of signalling lymphocyte activation molecule (SLAM) family receptors CS1 (CD319) and 2B4 (CD244) in patients with systemic lupus erythematosus.
2010 Jun
A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy.
2010 Mar
Successful treatment of MDS with lenalidomide, complicated by transient autoimmune hemolysis.
2010 Mar
Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma.
2010 May
Stroke after treatment with bortezomib and dexamethasone in a Chinese patient with extramedullary relapse of multiple myeloma.
2010 Nov
Activation of coagulation by lenalidomide-based regimens for the treatment of multiple myeloma.
2013
Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide.
2014 Aug 7
"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
2014 Jan
The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
2014 Jan 16
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
2015 May 18
Patents

Patents

Sample Use Guides

Multiple Myeloma:
Route of Administration: Oral
Lenalidomide enhances signaling via CAR19 receptor. To determine the costimulatory effect of lenalidomide, CAR19 T cells were stimulated with immobilized anti-CD3 antibody (clone MEM-57) or, with immobilized anti-CAR serum (polyclonal goat anti-mouse IgG FAB2) in the presence (10 MM, 1 MM) or absence of lenalidomide. The production of IFN in to culture supernatant was determined with ELISA after overnight co-incubation
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:27:53 UTC 2021
Edited
by admin
on Fri Jun 25 21:27:53 UTC 2021
Record UNII
F0P408N6V4
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LENALIDOMIDE
EMA EPAR   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
LENALIDOMIDE [EMA EPAR]
Common Name English
LENALIDOMIDE [ORANGE BOOK]
Common Name English
REVLIMID
Brand Name English
LENALIDOMIDE [INN]
Common Name English
LENALIDOMIDE [VANDF]
Common Name English
2,6-PIPERIDINEDIONE, 3-(4-AMINO-1,3-DIHYDRO-1-OXO-2H-ISOINDOL-2-YL)-
Systematic Name English
LENALIDOMIDE [MART.]
Common Name English
NSC-747972
Code English
CDC-501
Code English
LENALIDOMIDE [MI]
Common Name English
3-(4-AMINO-1-OXO-1,3-DIHYDRO-2H-ISOINDOL-2-YL)PIPERIDINE-2,6-DIONE
Systematic Name English
SYP-1512
Code English
LENALIDOMIDE [USAN]
Common Name English
CC-5013
Code English
LENALIDOMIDE [WHO-DD]
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS REVLIMID (AUTHORIZED: MULTIPLE MYELOMA)
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
NDF-RT N0000184014
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
FDA ORPHAN DRUG 476015
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
FDA ORPHAN DRUG 390813
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
FDA ORPHAN DRUG 147701
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
FDA ORPHAN DRUG 476115
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
FDA ORPHAN DRUG 230606
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
FDA ORPHAN DRUG 475915
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
FDA ORPHAN DRUG 180303
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
NCI_THESAURUS C1742
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
WHO-ATC L04AX04
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
NCI_THESAURUS C54677
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
EU-Orphan Drug EU/3/07/494
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
WHO-VATC QL04AX04
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
NCI_THESAURUS C129820
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
LIVERTOX 544
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
FDA ORPHAN DRUG 333811
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
FDA ORPHAN DRUG 278809
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
Code System Code Type Description
INN
8505
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
PUBCHEM
216326
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
DRUG CENTRAL
3317
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
NCI_THESAURUS
C2668
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
EVMPD
SUB25389
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
EPA CompTox
191732-72-6
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
RXCUI
342369
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY RxNorm
FDA UNII
F0P408N6V4
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
CAS
191732-72-6
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
HSDB
8220
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
DRUG BANK
DB00480
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
MERCK INDEX
M6760
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY Merck Index
MESH
C467567
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
ChEMBL
CHEMBL848
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
IUPHAR
7331
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
WIKIPEDIA
LENALIDOMIDE
Created by admin on Fri Jun 25 21:27:53 UTC 2021 , Edited by admin on Fri Jun 25 21:27:53 UTC 2021
PRIMARY
Related Record Type Details
BINDER->LIGAND
BINDING
TARGET -> INHIBITOR
BINDING
TARGET -> INHIBITOR
CRBN ubiquitination studies in the transfected HEK293T cells resulted in the following potencies: CC-220 IC50 = 0.19 ?M; lenalidomide IC50 = 12.9 ?M; and pomalidomide IC50 = 21.6 ?M.
BINDING
IC50
SALT/SOLVATE -> PARENT
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

Biological Half-life PHARMACOKINETIC